Pharmacologic modulation of bronchial vascular remodeling: Current therapies and novel approaches

Bronchial Vascular Remodeling in Asthma and COPD

Volumn , Issue , 2006, Pages 213-226

  Chetta, Alfredo ^a   Olivieri, Dario ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947627267     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993; 147: 405-410.
2. Takizawa T, Thurlbeck WM. Muscle and mucous gland size in the major bronchi of patients with chronic bronchitis, asthma, and asthmatic bronchitis. Am Rev Respir Dis 1971; 104: 331-336.
3. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997; 111: 852-857.
4. Dunnill MS. The pathology of asthma with special reference to changes in the bronchial mucosa. J Clin Pathol 1960; 13: 27-33.
5. Dunnill MS, Massarella GR, Anderson JA. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis and in emphysema. Thorax 1969; 24: 176-179.
6. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997; 156: 229-233.
7. Salvato G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001; 56: 902-906.
8. Wilson J. The bronchial microcirculation in asthma. Clin Exp Allergy 2000; 30: 51-53.
9. Moreno RH, Hogg JC, Pare PD. Mechanics of airway narrowing. Am Rev Respir Dis 1986; 133: 1171-1180.
10. National Institutes for Health. Global initiative for asthma. Publication number 95-3659. Bethesda, MD: National Institutes for Health, National Heart, Lung and Blood Institute, 1996.
11. Wang JH, Trigg CJ, Devalia JL, Jordan S, Davies RJ. Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium of patients with mild asthma. J Allergy Clin Immunol 1994; 94: 1025-1034.
12. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995; 152: 45-52.
13. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study.AmJ Respir Crit Care Med 1997; 155: 1864-1871.
14. Kumar SD, Emery MJ, Atkins ND, Danta I, Wanner A. Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998; 158: 153-156.
15. Kumar SD, Brieva JL, Danta I, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med 2000; 161: 918-921.
16. Ginsburg J, Duff RS. Influence of intra-arterial hydrocortisone on adrenergic responses in the hand. BMJ 1958; 16: 424-427.
17. Altura BM. Role of glucocorticoids in local regulation of blood flow. Am J Physiol 1966; 211: 1393-1397.
18. Rascher W, Dietz R, Scomig A, Burkart G, Gross F. Reversal of corticosteroneinduced supersensitivity of vascular smooth muscle to noradrenaline by arachidonic acid and prostacyclin. Eur F Parmacol 1980; 68: 267-273.
19. Chang PC, van der Krogt JA, van Brummelen P. Demonstration of neuronal and extraneuronal uptake of circulating norepinephrine in the forearm. Hypertension 1987; 9: 647-653.
20. ChettaA, ZaniniA, ForesiA, et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit CareMed 2003; 167: 751-757.
21. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999; 54: 289-295.
22. Orsida BE, Ward C, Li X, et al. Effect of a long-acting b2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164: 117-121.
23. Hoshino M, Takahashi M, Takai Y, Sim J, Aoike N. Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy 2001; 31: 722-730.
24. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascularspecific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
25. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001; 107: 1034-1038.
26. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341: 309-315.
27. Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol 2001; 425: 109-116.
28. Wen FQ, Liu X, Manda W, et al. TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol 2003; 111: 1307-1318.
29. Hashimoto S, Gon Y, Matsumoto K, Takeshita I, Maruoka S, Horie T. Inhalant corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells. Am J Respir Crit Care Med 2000; 162: 1075-1080.
30. Wilson SJ, Wallin A, Della-Cioppa G, Sandstrom T, Holgate ST. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001; 164: 1047-1052.
31. Hoshino S, Takahashi M, Takai Y, Sim J. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999; 104: 356-363.
32. Sorbo J, Jakobsson A, Norrby K. Mast-cell histamine is angiogenic through receptors for histamine1 and histamine 2. Int J Exp Pathol 1994; 75: 43-50.
33. Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med 1980; 152: 931-944.
34. Boesiger J, Tsai M, Maurer M, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med 1998; 188: 1135-1145.
35. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast cells migration. Blood 1995; 86: 2488-2493.
36. Hakonarson H, Grunstein MM. Regulation of second messengers associated with airway smooth muscle contraction and relaxation. Am J Respir Crit Care Med 1998; 158: S115-S122.
37. Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999; 104: S10-S17.
38. Chong LK, Cooper E, Vardey CJ, Peachell PT. Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 1998; 123: 1009-1015.
39. Borger P, Hoekstra Y, Esselink MT, et al. Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Am J Respir Cell Mol Biol 1998; 19: 400-407.
40. Munoz NM, Vita AJ, Neeley SP, et al. Beta adrenergic modulation of formylmethionine- leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4. J Pharmacol Exp Ther 1994; 268: 139-143.
41. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharideinduced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995; 48: 747-757.
42. Pang L, Knox AJ. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000; 23: 79-85.
43. Silvestri M, Fregonese L, Sabatini F, Dasic G, Rossi GA. Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. Eur Respir J 2001; 18: 139-145.
44. Tomlinson PR, Wilson JW, Stewart AG. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem Pharmacol 1995; 49: 1809-1819.
45. Proud D, Reynolds CJ, Lichtenstein LM, Kagey-Sobotka A, Togias A. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin Exp Allergy 1998; 28: 868-875.
46. Greiff L, Wollmer P, Andersson M, Svensson C, Person CG. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects. Thorax 1998; 53: 1010-1013.
47. Bolton PB, McDonald DM. Salmeterol reduces early and late phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 155: 1428-1435.
48. Baluk P, McDonald DM. The b2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol 1994; 266: L461-L468.
49. Aldridge RE, Hancox RJ, Robin Taylor D, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 2000; 161: 1459-1464.
50. Dente FL, Bancalari L, Bacci E, et al. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects. Thorax 1999; 54: 622-624.
51. Li X, Ward C, Thien F, et al. An anti-inflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493-1499.
52. Roberts JA, Bradding P, Britten KM, et al. The long-acting b2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14: 275-282.
53. Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010.
54. Reid DW, Ward C, Wang N, et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 2003; 21: 994-999.
55. Sabatini F, Silvestri M, Sale R, Serpero L, Di Blasi P, Rossi GA. Cytokine release and adhesion molecule expression by stimulated human bronchial epithelial cells are downregulated by salmeterol. Respir Med 2003; 97: 1052-1060.
56. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006-1008.
57. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907-1914.
58. Djukanovic R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J 1995; 8: 831-833.
59. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53: 835-841.
60. O’Sullivan S, Akveld M, Burke CM, Poulter LW. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation. Am J Respir Crit Care Med 2003; 167: 745-750.
61. Henderson WR, Jr., Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165: 108-116.
62. Mendes ES, Campos MA, Hurtado A, Wanner A. Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma. Am J Respir Crit Care Med 2004; 169: 1131-1134.
63. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-270.
64. Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003; 41: S63-S72.
65. O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
66. O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
67. O’Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-1928.
68. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792-3803.
69. McDonald DM. Angiogenesis and remodeling of airways vasculature in chronic inflammation. Am J Respir Crit Care Med 2001; 164: S39-S45.
70. Gamble JR, Drew J, Trezise L, et al. Angiopoietin-1 is an antipermeability and antiinflammatory agent in vitro and targets cell junctions. Circ Res 2000; 87: 603-607.
71. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463.